LeadIQ logo
Learn more at LeadIQ.com

Insights

Innovative Platform Biocytogen offers a cutting-edge antibody discovery platform powered by advanced gene editing technologies and a state-of-the-art animal facility, providing opportunities to enhance in-house R&D capabilities for pharmaceutical companies seeking efficient preclinical validation solutions.

Strong Industry Collaborations Collaborating with more than 70 percent of the top 50 global pharma firms indicates high credibility and potential for expanding licensing deals, joint ventures, or service outsourcing with large biotech and pharmaceutical enterprises.

Expanding Global Presence Participation in international industry events like BIO KOREA 2025 and IMMUNOLOGY AAI 2025 demonstrates proactive market engagement and opens doors for new partnerships and regional sales opportunities in Asia and North America.

Targeted Partnerships Recent collaborations with Acepodia and Radiance Bio for developing bispecific antibodies and ADCs highlight a growing focus on innovative therapeutic modalities, offering opportunities to sell specialized services or technology licenses in emerging antibody formats.

Financial Capability With a substantial funding of 286 million USD and revenues between 50 to 100 million USD, Biocytogen is equipped to invest in or adopt new technologies, presenting opportunities for long-term contracts, technology integration, or premium service offerings relevant to their growth trajectory.

Biocytogen Tech Stack

Biocytogen uses 8 technology products and services including Google AdSense, Cloudflare CDN, SAP, and more. Explore Biocytogen's tech stack below.

  • Google AdSense
    Advertising
  • Cloudflare CDN
    Content Delivery Network
  • SAP
    Customer Relationship Management
  • Google Fonts API
    Font Scripts
  • Asana
    Issue Trackers
  • Element UI
    Javascript Frameworks
  • Modernizr
    Javascript Libraries
  • Google Tag Manager
    Tag Management

Biocytogen's Email Address Formats

Biocytogen uses at least 1 format(s):
Biocytogen Email FormatsExamplePercentage
FLast@biocytogen.comJDoe@biocytogen.com
42%
First.Last@biocytogen.comJohn.Doe@biocytogen.com
8%
FLast@biocytogen.comJDoe@biocytogen.com
42%
First.Last@biocytogen.comJohn.Doe@biocytogen.com
8%

Frequently Asked Questions

Where is Biocytogen's headquarters located?

Minus sign iconPlus sign iconBiocytogen's main headquarters is located at 300 3rd Avenue Fl6 Waltham, Massachusetts 02451 United States. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is Biocytogen's phone number?

Minus sign iconPlus sign icon You can contact Biocytogen's main corporate office by phone at
+1-781-587-****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Biocytogen's stock symbol?

Minus sign iconPlus sign iconBiocytogen is a publicly traded company; the company's stock symbol is 2315.HK.

What is Biocytogen's official website and social media links?

Minus sign iconPlus sign iconBiocytogen's official website is biocytogen.com and has social profiles on LinkedInCrunchbase.

What is Biocytogen's SIC code NAICS code?

Minus sign iconPlus sign iconBiocytogen's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Biocytogen have currently?

Minus sign iconPlus sign iconAs of February 2026, Biocytogen has approximately 196 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Ceo: Y. S.Chief Operating Officer: M. L.Vice President Of Institute For Biologics, Biocytogen, Us And China: W. F. A.. Explore Biocytogen's employee directory with LeadIQ.

What industry does Biocytogen belong to?

Minus sign iconPlus sign iconBiocytogen operates in the Biotechnology Research industry.

What technology does Biocytogen use?

Minus sign iconPlus sign iconBiocytogen's tech stack includes Google AdSenseCloudflare CDNSAPGoogle Fonts APIAsanaElement UIModernizrGoogle Tag Manager.

What is Biocytogen's email format?

Minus sign iconPlus sign iconBiocytogen's email format typically follows the pattern of FLast@biocytogen.com. Find more Biocytogen email formats with LeadIQ.

How much funding has Biocytogen raised to date?

Minus sign iconPlus sign icon As of February 2026, Biocytogen has raised $286M in funding. The last funding round occurred on Aug 08, 2019 for $78M.

When was Biocytogen founded?

Minus sign iconPlus sign iconBiocytogen was founded in 2009.

Biocytogen

Biotechnology ResearchMassachusetts, United States51-200 Employees

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ mice), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with more than 70% of the top 50 pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world.

Section iconCompany Overview

Headquarters
300 3rd Avenue Fl6 Waltham, Massachusetts 02451 United States
Phone number
+1-781-587-****
Website
biocytogen.com
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
2315.HK
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2009
Employees
51-200

Section iconMedia & News

Section iconFunding & Financials

  • $286M

    Biocytogen has raised a total of $286M of funding over 3 rounds. Their latest funding round was raised on Aug 08, 2019 in the amount of $78Mas a series D.

  • $50M$100M

    Biocytogen's revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $286M

    Biocytogen has raised a total of $286M of funding over 3 rounds. Their latest funding round was raised on Aug 08, 2019 in the amount of $78Mas a series D.

  • $50M$100M

    Biocytogen's revenue is estimated to be in the range of $50M$100M

Company Leadership

  • Stylized image of a person
    Y. S.
    Ceo
    Phone icon
    Mobile Phone
  • Stylized image of a person
    M. L.
    Chief Operating Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    W. F. A.
    Vice President Of Institute For Biologics, Biocytogen, Us And China
    Phone icon
    Mobile Phone
  • Stylized image of a person
    T. J.
    President
    Phone icon
    Mobile Phone
  • Stylized image of a person
    T. G.
    Bd Associate Director Of Preclinical Cro Services, Apac Area
    Phone icon
    Mobile Phone

Employee Directory

  • Stylized image of a person
    C. G.
    R&d Director; Key Account Manager
    Phone icon
    Mobile Phone
  • Stylized image of a person
    F. C.
    Regional Director
    Phone icon
    Mobile Phone
  • Stylized image of a person
    L. K.
    Director Of In Vitro Platform
    Phone icon
    Mobile Phone
  • Stylized image of a person
    L. L. M.
    Director Of Licensing, Renmice Platforms
    Phone icon
    Mobile Phone
  • Stylized image of a person
    M. D.
    Director Of Product Development
    Phone icon
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.